'Patients develop T cell lymphomas after CAR-T therapy extremely rarely — less than 0.1% of the time, Rejeski said. Second cancers also rarely cause death in CAR-T patients, Rejeski said. Mortality from these subsequent cancers occurs roughly 0.5% of the time. In comparison, infections led to the deaths of about 4% of CAR-T patients in a study that Rejeski published in Nature Medicine this week. “Infections, infections, infections. This is the main driver of non-relapse mortality,” he said.'

https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss